PreciseBreast TM has the potential to deliver significant savings to payers and patients, while providing a more accurate measure of clinical risk; ultimately supporting treatment and management decisions for all patients with invasive breast cancer NEW YORK , July 23, 2024 /PRNewswire/ -- PreciseDx ®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced that its economic impact study for PreciseBreastTM risk assessment has been published in the July issue of the Journal of Medical Economics. The study calculated the cost impact of using PreciseBreastTM(also referred to as PDxBr), an AI histopathology platform that predicts the 6-year risk of recurrence in early-stage invasive breast cancer (IBC) patients to aid in the treatment decision process (i.e.
use of chemotherapy). The study compared the costs of treatment guided by standard of care (SOC) risk assessment (i.e.
, 21 gene expression test and histopathology assessment) versus PreciseBreastTM in conjunction with SOC. A hypothetical cohort of one million U.S.
women with early-stage invasive breast cancer was used for the study. Cost impact considered the cost of testing, adjuvant therapy, recurrence, adverse events, surveillance, and end-of-life care from a commercial payer perspective. The findings are compelling: when used as part of a recurrence risk evaluation in a hypothetical cohort of one million female members, use.